CHI launches NGS for Drugs, Patients and Clinical Trials Conference

[jhodges]

Next-Generation Sequencing (NGS) is poised to revolutionize the drug discovery paradigm by offering unprecedented interrogation of the human genome at high resolution and relatively low costs. While the widespread implementation of NGS is apparent, issues specific to drug development present new challenges for developers.

Join Cambridge Healthtech Institute for NGS for Drugs, Patients and Clinical Trials and explore the unparalleled advantages and arising challenges in using NGS technologies for translational research.

Discussions will cover:
- NGS for Decision Making During Drug Development and Clinical Trials
- Developing Informatics Infrastructure & Pipelines to Handle Complex NGS Data
- Navigating Regulatory Hurdles of Informed Consent and Data Sharing
- Harnessing NGS Technologies for Identification of Causal Variants and "Driver" Mechanisms in Disease

Featured presentations include:

Profiling and NGS in Cancer: Challenges and Applications to Targets, Models, and Resistance
Paul Rejto, Ph.D., Director, Computational Biology, Oncology Research Unit, Pfizer, Inc.

Devising Methods for Intuitively Handling Huge Data Sets to Simplify Biomarker Discovery
Dongliang Ge, Ph.D., Director, Bioinformatics, Gilead Sciences, Inc.

NGS for Drugs, Patients and Clinical Trials
March 21-22, 2013
Hilton San Diego Resort
San Diego, CA

http://www.healthtech.com/ngs-drug-development

Secure your place early to save.